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ABSTRACT
Epigenome-wide association studies (EWAS) are designed to characterise population-
level epigenetic diﬀerences across the genome and link them to disease. Most com-
monly, they assess DNA-methylation status at cytosine-guanine dinucleotide (CpG)
sites, using platforms such as the Illumina 450k array that proﬁle a subset of CpGs
genome wide. An important challenge in the context of EWAS is determining a signif-
icance threshold for declaring a CpG site as diﬀerentially methylated, taking multi-
ple testing into account. We used a permutation method to estimate a signiﬁcance
threshold speciﬁcally for the 450k array and a simulation extrapolation approach
to estimate a genome-wide threshold. These methods were applied to ﬁve diﬀerent
EWAS datasets derived from a variety of populations and tissue types. We obtained
an estimate of 𝛼 = 2.4 × 10−7 for the 450k array, and a genome-wide estimate of
𝛼 = 3.6 × 10−8. We further demonstrate the importance of these results by showing
that previously recommended sample sizes for EWAS should be adjusted upwards,
requiring samples between ∼10% and ∼20% larger in order to maintain type-1 errors
at the desired level.
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1 INTRODUCTION
Epigenetic marks are mitotically heritable chemical modiﬁ-
cations to DNA and histone proteins, which act in concert to
regulate gene expression across developmental stages and tis-
sues (Bird, 2002). The most widely studied of these marks is
DNA methylation, describing the addition of a methyl group
to the ﬁve carbon of cytosine bases to form 5-methylcytosine
(5mC), occurring predominantly in the context of CpG
dinucleotides. DNA methylation plays a crucial role in
cellular processes such as embryonic development, parental
imprinting and X-inactivation. Aberrant methylation patterns
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have been associated with a number of diseases (Robertson,
2005), and variation in methylation between individuals
could potentially explain a proportion of phenotypic variance
(Rakyan & Beck, 2006). These observations in particular
have led to the popularisation of epigenome-wide association
studies (EWAS), which proﬁle methylomic variation genome
wide in the context of normal development and in disease
(Rakyan, Down, Balding, & Beck, 2011).
The growth of EWAS can be at least partially attributed
to the introduction of the Illumina Inﬁnium HumanMethy-
lation450k BeadChip (450k array) (Illumina, San Diego,
CA, USA). The 450k array is a low-cost, high-throughput,
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platform that interrogates around 450,000 individual CpG
sites across the genome, covering <2% of all known CpG
sites, and 99% of RefSeq genes (see Dedeurwaerder et al.,
2011, for a description of the technology). The platform has
been used in investigations into the role of methylomic vari-
ation across a range of phenotypes and health conditions
including cancers (Heyn et al., 2013; Walter et al., 2012),
autoimmune disorders (Liu et al., 2013; Swan, Maxwell,
& McKnight, 2015), psychiatric conditions (Feinberg et al.,
2015; Song et al., 2014; Walton et al., 2015), age-related
phenotypic changes (Florath, Butterbach,Müller, Bewerunge-
Hudler, & Brenner, 2014) and environmental exposures (Jou-
bert et al., 2014; Laufer et al., 2015; Silver et al., 2015).
More recently, Illumina have introduced the Inﬁnium Methy-
lationEPIC BeadChip – which oﬀers approximately double
the coverage of the 450k (Moran, Arribas, & Esteller, 2016).
Although future studies will adopt the latest platform, the
majority of publicly available datasets are from the 450k; such
datasets are still being generated, so that 450k data will con-
tinue to be analysed for years to come.
For such studies, as was previously the case with genome-
wide association studies (GWAS) of single nucleotide poly-
morphisms (SNPs), the development of standardised experi-
mental design protocols and statistical methods is crucial for
ensuring that reported ﬁndings are robust, reproducible, and
biologically relevant (Michels et al., 2013; Mill & Heijmans,
2013; Rakyan et al., 2011). Although there are signs that ana-
lytical frameworks are beginning to crystallise for EWAS,
there is one particular aspect that has not received much atten-
tion, and that is the level of evidence required for an identi-
ﬁed diﬀerence in mean methylation levels of a CpG between
experimental conditions (a diﬀerentially methylated position,
DMP) to reach genome-wide signiﬁcance. By contrast, early
standardisation of the genome-wide signiﬁcance threshold
was a key factor in the immediate success of GWAS (Dud-
bridge & Gusnanto, 2008; Hoggart, Clark, De Iorio, Whit-
taker, & Balding, 2008; Pe'er, Yelensky, Altshuler, & Daly,
2008).
Establishment of a signiﬁcance level for EWAS is compli-
cated by the fact that multiple CpG sites are tested for associa-
tion simultaneously, and that sites in close proximity can have
correlatedmethylation states (co-methylation) at genomic dis-
tances of up to 1–2 kb (Eckhardt et al., 2006; Kuan & Chi-
ang, 2012; Ong & Holbrook, 2014). These problems of mul-
tiple testing and dependence have previously been addressed
in GWAS studies; however, there is no counterpart in EWAS
of the well-understood phenomenon of linkage disequilib-
rium (LD) that underpins GWAS. In the case of LD, shared
ancestry is responsible for the correlation between SNPs,
whereas the precise mechanism generating co-methylation is
unknown. It is entirely possible that LD could itself be gen-
erating dependency between CpG sites based on their physi-
cal proximity. Indeed, a previous study found that some sets
of correlated methylated CpG sites appeared to be associated
with SNPs in LD blocks (Liu et al., 2014). The extent of co-
methylation might also depend on functional context (Schild-
knecht, Olek, & Dickhaus, 2015). For example, sites located
in CpG islands (regions of high CpG density, often found in
gene promoters) would be expected to display a high degree
of co-methylation, as combined they form a functional unit
involved in gene silencing.
The presence of a correlation structure within methylation
data has at least two major implications for downstream anal-
ysis. First, for single site-level analysis, dependence between
measures should be taken into account when estimating a
signiﬁcance threshold. Second, the existence of correlated
blocks of methylated CpGs can alternatively be exploited as
a means for grouping together multiple sites into regions.
The goal of such an analysis is then to identify diﬀeren-
tially methylated regions (DMRs), which might be preferred
over an individual site-level analysis aiming to identify DMPs
(Rakyan et al., 2011; Robinson et al., 2014; Jaﬀe et al.,
2012).
Regional analysis has two major limitations that perhaps
explain why EWAS results still tend to report diﬀerential
methylation for individual CpGs. Some of the more popular
regional methods are optimised for data generated by speciﬁc
platforms. For example, the “bump hunting” method of Jaﬀe
et al. (2012) when applied to 450k data covers only around
20% of the CpGs proﬁled on the array (Ong & Holbrook,
2014). Even in cases where the method is designed for the
speciﬁc platform in question, there is no guarantee that all
CpGs can be assigned to regions. This is because CpG sites are
distributed non-uniformly throughout the genome in regions
of both high and low density; therefore, it is likely that a
number of sites will not form part of any correlated blocks.
Ong and Holbrook (2014) found that their region detection
method, though designed for the 450k, does not include 24%
of the probes on the array, leading the authors to suggest that
single probe analysis should be performed alongside region
discovery to maximize discovery of diﬀerential methylation
signals.
For these reasons, we focus here on a signiﬁcance thresh-
old for single site analysis. Previously Tsai, Spector, and Bell
(2012) suggested that a Bonferroni-adjusted threshold of 𝛼 =
10−7, accounting only for those CpGs tested on the 450k,
would be overly conservative, and recommended false dis-
covery rate or permutation methods for controlling the error
rate until a consensus is established. Rakyan et al. (2011) pro-
posed a liberal threshold of 𝛼 = 10−6, based on a hypothet-
ical set of 500,000 CpG probes with suﬃcient and uniform
spacing between probes such that independence of individ-
ual measurements is assumed. However, the authors acknowl-
edged that due to correlation between neighbouring CpG sites,
a more formal estimation is required, and a stringent level is
more likely to lie between 10−8 and 10−7.
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TABLE 1 Details about the ﬁve 450k datasets used
Dataset GEO accession Population Tissue Age Status N
Gambian GSE59592 African-Gambian Blood 2–8 months Healthy 120
CRC N/A Caucasian-European Colon/rectum 58–80 years Colorectal cancer 18
Caucasian GSE40279 Caucasian-European Blood 19–101 years Healthy 426
Afr-Am-GTP GSE72680 African-American Blood 13–48 years Healthy/Depression/Bipolar 422
Cau-Am GSE41826 Caucasian-American Brain 13–79 years Healthy 65
In the context of GWAS, it was argued that the responsible
use of a 𝑃 -value threshold should allow for all polymor-
phisms across the genome (Dudbridge & Gusnanto, 2008),
not only those tested, an argument which applies equally
well to EWAS. Essentially, the prior odds of association
for any single CpG depend on the total multiplicity of
the methylome, not the number present on a commercial
product. The methylome has multiplicity of roughly the same
order of magnitude as SNPs in the genome with approx-
imately 28 million CpG sites that could be interrogated,
although technologies such as the 450k and EPIC measure far
fewer.
Without knowledge of the correlation generating mech-
anism in EWAS, we apply the simulation extrapolation
approach of Dudbridge and Gusnanto (2008) to several real
450k DNA methylation datasets to estimate signiﬁcance
thresholds for a hypothetical array with inﬁnite CpG site den-
sity. We consider a variety of study populations and cell types
to generate speciﬁc signiﬁcance thresholds before drawing a
consensus across the studies.
2 MATERIALS
The DNA methylation datasets used here were taken from ﬁve
existing EWAS which utilised the 450k array, see Table 1.
Two of these were recent studies in which some of us have
been involved, and the remaining three were taken from pub-
licly available datasets deposited in the NCBI Gene Expres-
sion Omnibus (http://www.ncbi.nlm.nih.gov/geo/), accessed
and downloaded using the R package marmal-aid (http://
marmal-aid.org) (Lowe & Rakyan, 2013). These studies were
selected as some of the largest publicly available datasets rep-
resenting diﬀerent ancestral populations and cell types at the
time of carrying out the study.
For each of the datasets, the matrix of processed 𝐵𝑒𝑡𝑎 val-
ues was provided or downloaded. These were used without
any further processing in order to assess correlation structure.
For permutation testing, these were converted to 𝑀 values,
which have previously shown to possess more desirable distri-
butional properties for diﬀerential methylation analysis when
compared to 𝐵𝑒𝑡𝑎 values (Du et al., 2010). The following for-
mula was used to convert from 𝐵𝑒𝑡𝑎 to 𝑀 (Du et al., 2010):
𝑀𝑖 = log2
(
𝐵𝑒𝑡𝑎𝑖(
1 − 𝐵𝑒𝑡𝑎𝑖
)) . (1)
The ﬁrst dataset, referred to as ‘Gambian’, comes from an
investigation into the eﬀect of in utero exposure to aﬂatoxin
B1 on DNA methylation patterns in a mother/child cohort
from The Gambia (Hernandez-Vargas et al., 2015). Genome-
wide methylation proﬁles were generated from peripheral
blood samples for 120 infants between 2 and 8 months of age.
The data were provided in the form of a matrix of processed
𝐵𝑒𝑡𝑎 values, which had undergone quality control and nor-
malisation. Full details on the experimental protocol and anal-
ysis method can be found elsewhere (Hernandez-Vargas et al.,
2015).
The second dataset, ‘CRC’, is taken from a study char-
acterising methylation patterns in 18 cases of colorectal
carcinoma and four control samples of intestinal mucosa
from a European Caucasian population (PZ, LM, AC,
unpublished work). An Illumina GenomeStudio report was
provided, which contained raw probe intensities, this was
ﬁrst processed using the methylumi package in R (Davis, Du,
Bilke, Triche, & Bootwalla, 2012) to perform colour balance
adjustment and quantile normalisation, and to generate a
matrix of 𝐵𝑒𝑡𝑎 values. Control samples were removed due
to the high level of discordance expected between cases
and controls – a result of abberant CpG island methylation
(Costello et al., 2000) and other large-scale methylomic
alterations expected in the CRC cases (Uhlmann et al., 2003).
The resulting dataset contained only the 18 cases.
A further three datasets were identiﬁed by searching the
marmal-aid database for healthy controls from Caucasian or
African populations, and then repeating the same search this
time querying the GEO database directly. Two datasets were
identiﬁed in marmal-aid, the ﬁrst, ‘Caucasian’, comes from a
study into age-related changes to methylomic state as proﬁled
in peripheral blood samples from 426 Caucasian individuals,
spanning a wide range of ages (Hannum et al., 2013) (GEO
accession number: GSE40279). The second, ‘Cau-Am’, is
from an unknown study (incomplete annotation in marmal-
aid) consisting of 65 Caucasian-American controls. For all of
these marmal-aid datasets, processed 𝐵𝑒𝑡𝑎 values were used
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which had undergone quantile normalization and imputation
of missing probes (see Lowe & Rakyan, 2013, for further
details). These data were taken forward for analysis without
any further processing. The ﬁnal set identiﬁed on GEO,
‘Afr-Am-GTP’, is from a study utilising 422 healthy individ-
uals from the Grady Trauma Project, investigating the eﬀect
of lifetime exposure to stress on prevalence of psychiatric
disorders in a predominantly African American population
(Gillespie et al., 2009) (GEO accession: GSE72680). The
processed Beta matrix was downloaded and used without
further processing.
3 METHODS
3.1 Correlation structure
To begin with, the correlation structure within each methy-
lation dataset was qualitatively assessed. This was performed
ﬁrst to demonstrate the existence of correlation between adja-
cent CpGs in the datasets, and second to identify any poten-
tial large-scale diﬀerences in correlation structure between the
datasets, which might be attributable to the diﬀerent tissues,
ethnicities, or conditions studied.
For each dataset, the following procedure was carried out
to determine the level of correlation between adjacent probes.
Using the subset of 46K probes mapping to chromosome
1, Pearson's correlation between each of the probe 𝐵𝑒𝑡𝑎
values was calculated. Next, pairwise inter-probe distances
were calculated by taking the absolute diﬀerences between
the genomic positions of the CpGs (in bp) as given in the
450k manifest (from the R package illuminahumanmethyla-
tion450k; Triche, 2012). This list of inter-pair distances was
ﬁltered in order to retain only those with distance less than or
equal to 10,000 bp. These remaining probe pairs were then
divided into approximately 10,000 bins containing around
400 pairs each, and the median pairwise inter-probe distance
of the bin recorded. The mean pairwise correlation of 𝐵𝑒𝑡𝑎
values per bin was also recorded.
3.2 Permutation scheme
For each dataset, and for all probes on the array, a permuta-
tion scheme was used to generate an empirical null distribu-
tion of 𝑡-test values from which a per-CpG signiﬁcance level
𝛼 could be derived. The 𝑡-test is commonly used in EWAS,
as it seems to be robust to the non-normality of methylation
𝑀 values (Du et al., 2010) and provides greater power than
non-parametric methods.
Further details on the algorithms used for permutation and
subsampling are given in the Supplementary material, but
brieﬂy: phenotypic labels were randomly assigned to sam-
ples, for sample size 𝑛 ∶ ⌊𝑛∕2⌋ were designated as cases and⌈𝑛∕2⌉ as controls. The labels were then randomly permuted
10,000 times, and for each of these permutations, independent
unrelated sample 𝑡 tests were performed for each CpG and the
absolute 𝑡 values recorded.
In order to estimate the signiﬁcance threshold at the
density of CpGs present on the 450k array, the maximum
𝑡-test statistic scores for each permutation were taken and
corresponding 𝑃 values were calculated (under the assump-
tion of equal variance), and 𝛼 taken as the 5th percentile of
the distribution of minimum 𝑃 values.
3.3 Eﬀective number of independent tests
The eﬀective number of independent tests is the number 𝑚
required to obtain the observed 𝛼 using the Bonferroni cor-
rection:
𝑚 = 0.05∕𝛼. (2)
This was calculated for each 𝛼 derived from the permutation
data. To test whether the observed data were consistent with
there being an eﬀective number of independent tests, a beta
distribution was ﬁtted for each set of permutation minimum
𝑃 values. Under these assumptions, the minimum 𝑃 values
from the permutation replicates would be expected follow a
beta distribution with parameters:
𝛽(𝑎 = 1, 𝑏 = 𝑚′), (3)
corresponding to the Šidák correction:
1 − (1 − 𝛼)𝑚′ . (4)
The parameters 𝑎 and 𝑏 of the beta distribution can be esti-
mated using the following method of moments estimators:
?̂? = ?̄?
(
?̄? (1 − ?̄?)
𝑠2
− 1
)
, (5)
?̂? = (1 − ?̄?)
(
?̄? (1 − ?̄?)
𝑠2
− 1
)
, (6)
where ?̄? and 𝑠2 are the sample mean and variance of the min-
imum 𝑃 values over the permutations.
Fixing the value of 𝑎 to be 1, the estimate for 𝑏 is:
?̂? = 1 − ?̄?
?̄?
. (7)
Maximum likelihood estimation of 𝛽(1, ?̂?) was then per-
formed using the optim function in R, using the methods of
moments estimate as the starting point, to obtain a ﬁnal esti-
mate of 𝑚′, which was compared to the value of 𝑚 obtained
from the Bonferroni equation given above.
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3.4 Estimation of genome-wide thresholds
For each set of permutation results, a subsampling procedure
was used to extrapolate the ﬁndings to a theoretical array of
inﬁnite density (Dudbridge & Gusnanto, 2008). For each per-
mutation, the 𝑃 values were sampled over a uniform grid
of 100 densities from 0 to 1, in increments of 0.01, and the
minimum 𝑃 value at each density recorded. This procedure
was repeated 100 times, and for each of these 100 replicates,
the 5% point at each density across all the permutations was
recorded. The mean 5% point for each density across all 100
replicates was then used in subsequent analysis.
At lower densities, it would be expected that the majority
of sites are not adjacent to each other, and therefore, overall
levels of correlation are likely to be low. In this scenario,
increasing density will increase the number of independent
tests performed, and according to the Bonferroni law, the
5% point should decrease in a manner inversely proportional
to the density. However, for higher densities, the level of
correlation will increase and as the coverage approaches satu-
ration, the 5% point is expected to converge to an asymptote,
which represents 𝛼 for the entire genome.
To obtain estimates for the asymptote, the Monod function
was ﬁtted to each set of eﬀective numbers of tests 𝑚 across
the range of densities (Dudbridge & Gusnanto, 2008). The
Monod function was initially devised to model the growth of
microorganisms, but ﬁnds application in other systems where
growth is limited by availability of resources. Here, growth
can be thought of as the increase in eﬀective number of tests,
which is limited by site density. The equation takes the form:
𝑓 (𝑥; 𝑢, 𝑘) = 𝑢𝑥
(𝑘 + 𝑥)
, (8)
where 𝑢 is the limit as 𝑥→ ∞, and 𝑘 is the value for 𝑥 for
which
𝑓 (𝑥) = 𝑢∕2, (9)
it is also known as the half saturation parameter. This function
was ﬁtted to the calculated values of 𝑚 with the parameters
estimated by least squares and the genome-wide 𝛼 estimated
as:
𝛼 = 0.05∕𝑢. (10)
Both the permutation and subsampling methods were
implemented as python command-line tools with support
for multi-processing and memory-mapping to reduce com-
putation time and memory requirements. These are available
for download from the ﬁrst author's github: https://github.
com/asaﬀa/
TABLE 2 Permutation results showing the 5th percentile of the
minimum 𝑃 values from 10,000 permutations of the datasets, 𝑚 is the
eﬀective number of tests that this 5% point represents according to the
Bonferroni law, and 𝑏 is the estimated 𝑏 parameter after ﬁtting a beta
distribution
Dataset 𝒏 𝜶 𝒎 𝒃
Gambian 120 2.04E−07 245,563 170,286
CRC 18 3.53E−08 1,417,410 161,402
Caucasian 426 2.44E−07 204,586 153,670
Afr-Am-GTP 422 2.45E−07 204,046 124,186
Cau-Am 65 3.59E−07 139,451 70,782
3.5 Sample size estimation
Tsai and Bell (2015) estimated sample size requirements for
case-control and disease-discordant MZ twin design EWAS
based on power simulations across a range of diﬀerent sam-
ple sizes and eﬀect sizes. The simulations were performed
using both 𝑡-test and Wilcoxon tests, for nominal (𝑃 = 0.05)
and genome-wide (𝑃 = 1 × 10−6) signiﬁcance levels. We re-
calculated the sample sizes required for 80% power using our
empirical estimates of genome-wide 𝛼.
To this end, the non-central 𝑡 distributions giving rise to
the estimates were inferred from the reported results (table 2
in Tsai and Bell (2015)), and then used to calculate sample
sizes for our estimated signiﬁcance thresholds. The following
equation was used:
1 − 𝛽 = 1 − 𝐹(𝑛−1,𝑛𝑐𝑝)(𝑡(1−𝛼∕2)) + 𝐹(𝑛−1,𝑛𝑐𝑝)(−𝑡(1−𝛼∕2)), (11)
where 1 − 𝛽 = 0.8, 𝐹(𝑛−1,𝑛𝑐𝑝) is the cumulative distribution
function of the non-central 𝑡 distribution with 𝑛–1 degrees of
freedom and non-centrality parameter 𝑛𝑐𝑝, given by:
𝑛𝑐𝑝 =
√
𝑛 × 𝛿
𝜎
, (12)
and 𝑡(1−𝛼∕2) the critical value when 𝛼 = 1 × 10−6. Treated as
an optimization problem, this was solved for 𝜎 across the
range of sample sizes 𝑛 and mean methylation diﬀerences 𝛿.
These estimates were then used in another optimization, this
time solving to obtain sample sizes for each 𝛿 using the empir-
ically derived estimates of 𝛼.
4 RESULTS
4.1 Correlation structure
The correlation structure was assessed for each dataset. The
plots in Figure 1 show the overall patterns of correlation
between methylation status (𝐵𝑒𝑡𝑎) of pairs of CpG sites from
chromosome 1 as a function of genomic distance. The rela-
tionship between these variables appears consistent across
6 SAFFARI ET AL.
F IGURE 1 Correlation versus genomic distance for pairs of probes in chromosome 1
Notes: (A) Gambian, (B) CRC, (C) Caucasian, (D) Afr-Am-GTP, (E) Cau-Am.
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datasets. The curves show the same characteristic shape with
pairs in close proximity having the highest average levels of
correlation, tailing oﬀ sharply as distances approach 1 kb,
and then decreasing more slowly from 1 to 2 kb, appearing
to reach a limit just above zero – assumed to be the mean
background level of correlation across the genome. In terms
of the actual mean per bin correlation values, these appear
comparable across the datasets, with the exception of the CRC
set, with the approximate maximum per bin correlations of
0.3, 0.55, 0.4, 0.33, 0.4 and approximate background levels
of 0.07, 0.12, 0.04, 0.05, 0.07 for Gambian, CRC, Caucasian,
Afr-Am-GTP and Cau-Am sets, respectively. There are also
diﬀerences in the variability and spread of correlation values
between neighbouring bins, perhaps indicating diﬀerences in
apparent level of noise between sets.
4.2 Permutation and eﬀective number of tests
The results from the permutation testing scheme are given
in Table 2. The 5% points of the minimum 𝑝 distributions
vary between the diﬀerent datasets. The 𝛼s obtained for Gam-
bia, Caucasian, Afr-Am-GTP and Cau-Am are larger than the
Bonferroni adjusted 5% threshold of 𝛼 = 1.07 × 10−7, while
for CRC, this is smaller by almost a factor of 10. Investigat-
ing further, Figure 2 shows QQ plots of the observed min-
imum 𝑃 distributions against the expected quantiles of the
𝛽(1, 467, 624) distribution, which assumes the tests are inde-
pendent. From these plots, it can be observed for the Gambia,
Caucasian, Afr-Am-GTP and Cau-Am sets that while Bon-
ferroni correction produces uniformly distributed 𝑃 values,
these are also deﬂated over the entire range. For the CRC set,
it appears that the observed data are not at all well modelled
by the beta distribution, and there is not a clear pattern of over
or under correction of 𝑃 values, as they appear both deﬂated
at low values and inﬂated at higher values.
Converting these 5% points to eﬀective number of tests
yields results that are not in close agreement to those obtained
by ﬁtting the beta distribution. This suggests that the beta dis-
tribution with parameters (1, 𝑚) does not adequately model
the minimum 𝑃 value distribution for 𝑚 tests, and thus, while
it is a useful modelling tool, there is not a true underlying
eﬀective number of independent tests. The results for CRC
do not produce the expected distribution of min 𝑃 values, and
the estimated values for 𝛼, 𝑚 and 𝑏 show little resemblance
to the values obtained for the other datasets, indicating poten-
tial problems with this particular set. This is perhaps not sur-
prising given that this dataset is very diﬀerent to the others,
not only in disease status and tissue type, but also in having
a much smaller sample size. To determine the eﬀect of sam-
ple size on the success of the modelling strategy, we repeated
the experiment with another small control dataset from an
African American population (𝑛 = 12) from GSE41826 (the
same study from which the Cau-Am set was drawn). This
similarly was not well modelled by the beta distribution, also
producing an unusually large estimate for the𝑚 parameter and
resulting in 𝛼 of the same magnitude as that obtained for CRC
(see supplementary material).
Assuming the results from the limited analysis of correla-
tion structure performed here are more generalisable, there
appear to be only negligible diﬀerences between the over-
all patterns of co-methylation in the data from the diﬀerent
populations. Therefore, the estimated thresholds for the four
groups producing permutation data most closely ﬁtting the
expected distribution, Gambian, Caucasian, Afr-Am-GTP and
Cau-Am,would seem to be appropriate for combining in order
to derive a single ﬁgure. Taking the weighted mean of the
diﬀerent estimates for eﬀective number of tests yields a 450k-
speciﬁc threshold of: 𝛼 = 2.4 × 10−7.
4.3 Subsampling and genome-wide threshold
For subsampling, Figure 3 shows the resulting plots of the
mean 5th percentile of the sampled minimum 𝑃 values at
each subsampling density. The asymptotes were estimated by
ﬁtting the Monod function to the eﬀective number of tests,
the closeness of the ﬁt can be seen in Figure 4. The resulting
estimates for 𝑢, the limit as the density approaches inﬁnity,
and 𝑘, the value for 𝑥 at which half of genome-wide multi-
plicity is accounted for, are given in Table 3. The asymptotes
are shown in Figure 3. It was not possible to ﬁt the Monod
function to the CRC data. Once again, assuming the results
from correlation assessment are more generally applicable,
and that there areminimal diﬀerences in overall patterns of co-
methylation between the Gambian, Caucasian, Afr-Am-GTP
and Cau-Am populations, the weighted mean of the diﬀerent
estimates for the eﬀective number of test can be calculated,
giving a genome-wide 𝛼 = 3.6 × 10−8.
4.4 Sample size estimation
Results for the sample size estimations are given in
Table 4 alongside the original ﬁndings from Tsai & Bell,
2015. Using the 450k-speciﬁc 𝛼 = 2.4 × 10−7 increases the
sample size estimates by ∼10% over those estimated from
power simulations using the suggested threshold of 𝛼 = 1 ×
10−6. With the estimated genome-wide 𝛼 = 3.6 × 10−8, the
sample size estimates are ∼20% larger.
5 DISCUSSION
In this paper, we ﬁrst examined the correlation structure in
ﬁve 450k datasets of varying ethnicity and cell types, and then
empirically estimated signiﬁcance thresholds both speciﬁc to
the 450k array product and more generally for any EWAS
study.
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F IGURE 2 QQ plots showing observed distribution of minimum P values verses the expected distribution under complete independence
Notes: (A) Gambian, (B) CRC, (C) Caucasian, (D) Afr-Am-GTP, (E) Cau-Am.
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F IGURE 3 Signiﬁcance threshold as a function of CpG site density following the subsampling procedure
Notes: Where possible, the Monod function was ﬁtted to estimate an asymptote representing the threshold at fully saturated CpG density, this is
indicated by a dashed line. (A) Gambian, (B) CRC, (C) Caucasian, (D) Afr-Am-GTP, (E) Cau-Am.
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F IGURE 4 Estimated number of tests as a function of CpG site density
Notes: Where possible, the Monod function was ﬁtted, this ﬁt is shown by the blue line. (A) Gambian, (B) CRC, (C) Caucasian, (D) Afr-Am-GTP, (e)
Cau-Am.
The results of the correlation analysis reveal a distinc-
tive relationship, whereby proximal sites, up to a distance
of around 1 kb apart, show a moderate level of correla-
tion in the ∼0.25 to ∼0.4 range, falling to background levels
once inter-pair distances reach around 2 kb. These results are
consistent with previous ﬁndings, which have found moder-
ate to strong correlations of between 0.26 (Jaﬀe et al., 2012)
and 0.45 (Ong & Holbrook, 2014) extending over genomic
distances of between 1 and 2 kb (Eckhardt et al., 2006; Jaﬀe
et al., 2012; Kuan & Chiang, 2012; Ong & Holbrook, 2014).
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TABLE 3 Results from subsampling, showing the ﬁnal values for
the 𝑢 and 𝑘 parameters after ﬁtting the Monod function, and the asymp-
tote representing the genome-wide signiﬁcance threshold alpha
Dataset 𝒖 𝒌 Genome-wide 𝜶
Gambian 1.38E+06 4.71E+00 3.61E−08
CRC N/A N/A N/A
Caucasian 1.18E+06 4.79E+00 4.25E−08
Afr-Am-GTP 1.75E+06 7.61E+00 2.86E−08
Cau-Am 6.38E+05 3.54E+00 7.83E−08
There do not appear to be any large-scale diﬀerences in
overall patterns of co-methylation between brain and blood
when comparing the Cau-Am and Caucasian datasets, or
between Gambian, Caucasian and African American pop-
ulations when comparing the corresponding datasets. Only
the CRC dataset shows some slight diﬀerences. Although it
would be tempting to link this to the disease, such a result
could perhaps equally arise from the smaller sample size,
tissue heterogeneity or indeed data heterogeneity, especially
given that all the datasets are taken from independent studies.
Diﬀerences in the variability between sets are also apparent,
with the spread of correlation values between adjacent bins of
pairs showing a greater spread for the datasets having smaller
sample sizes. Once again, this is merely speculated, as it is not
possible to rule out data heterogeneity as the driver of such
diﬀerences.
As far as we are aware, this has been the ﬁrst attempt to
characterise the overall patterns of co-methylation between
CpGs in the context of diﬀerent tissues, ethnicities and dis-
ease states. The indications here are that there are unlikely to
be any large-scale diﬀerences in terms of the overall patterns
of co-methylation across tissues and ethnicities considered.
There are however observable diﬀerences in co-methylation
patterns in the case of colorectal cancer. This is perhaps not all
that surprising, given that large-scale methylomic disruption
is a hallmark of cancer (Sharma, Kelly, & Jones, 2010). How-
ever, before drawing any more general conclusions about the
nature of this disruption and how it might relate to overall pat-
terns of co-methylation, further experimental work would be
required. This could involve the collection of further samples
and the generation of data under rigorously controlled con-
ditions accounting for known sources of technical variation
(e.g., batch eﬀects) and confounding (such as age and smok-
ing). Further, co-methylation could be studied in a context-
speciﬁc manner, by categorising sites into CpG island, shores,
shelves, and singletons.
We used a permutation scheme to generate a null distribu-
tion of test statistics and obtain values for 𝛼 for each dataset.
By using such a scheme, we were also able to circumvent
issues concerning confounding due to technical and batch
eﬀects as well as cell type heterogeneity – usually impor-
tant considerations in EWAS more generally. As an addi-
tional advantage, by electing to use only minimal statistical
modelling, we are better able to demonstrate the robustness
of the methods and maximise the potential applicability of
the derived threshold. As for the results of the permutations,
inspecting the ﬁt of the beta distribution 𝛽(1, 467, 264) to the
minimum 𝑃 values generated, we see that the CRC dataset
deviates from the expected distribution quite markedly. This
was taken to indicate that this set did not produce reliable
results, possibly due to its smaller sample size. For the Gam-
bian, Caucasian, Afr-Am-GTP and Cau-Am datasets, the beta
distribution produced 𝑃 values consistently inﬂated over the
range, which suggests that an improved ﬁt might be achieved
by adjusting the second parameter of the beta distribution –
in other words, changing the eﬀective number of independent
tests.
Looking now at the 5% values obtained, for the Gam-
bian, Caucasian, Afr-Am-GTP and Cau-Am sets, these are
all larger than the Bonferroni adjusted 5% threshold of
𝛼 = 1.07 × 10−7. Assuming that the results and conclusions
TABLE 4 Sample size estimates based on those presented in Tsai and Bell (2015) (those indicated by an asterisk) using the estimates for 450k
and genome-wide signiﬁcance derived in this study
Discordant twin Case-control
Diﬀ 𝑷 < 𝟎.𝟎𝟓∗ 𝑷 < 𝟏 × 𝟏𝟎−𝟔∗ 𝑷 < 𝟐.𝟒 × 𝟏𝟎−𝟕 𝑷 < 𝟑.𝟔 × 𝟏𝟎−𝟖 𝑷 < 𝟎.𝟎𝟓∗ 𝑷 < 𝟏 × 𝟏𝟎−𝟔∗ 𝑷 < 𝟐.𝟒 × 𝟏𝟎−𝟕 𝑷 < 𝟑.𝟔 × 𝟏𝟎−𝟖
7 30 178 196 219 37 211 232 259
8 25 145 159 178 30 169 186 208
9 20 117 129 144 24 137 150 168
10 17 98 108 121 20 112 123 138
11 15 81 89 100 17 96 105 118
12 13 71 78 88 15 80 88 98
13 11 63 69 78 13 70 77 86
14 10 55 61 68 11 61 67 75
15 9 50 55 62 10 54 59 66
Diﬀ is the percentage mean methylation diﬀerence between case and control, twin and case-control refer to the study designs, and for each of the signiﬁcance thresholds,the
sample sizes required to achieve a power of 0.8 are given.
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from the assessment of correlation within the diﬀerent sets
are more generally applicable, and that there are no major
diﬀerences between diﬀerent populations, then the results
from these four sets can be combined to give a weighted mean
of 𝛼 = 2.4 × 10−7. From permutation testing results, we con-
clude that a signiﬁcance threshold of 𝛼 = 2.4 × 10−7 would be
appropriate for the 450k, accounting for the subset of probes
tested on the array but not the hypothetical set of probes that
could be tested with saturated genome-wide coverage.
To address the issue of genome-wide multiplicity, we used
a subsampling method to extrapolate the results of permu-
tation testing to an array of inﬁnite density. The results of
ﬁtting the Monod function to the subsampling data revealed
that the limit for the number of tests as the coverage on the
array becomes saturated is in the region of 1 × 106, that is,
1 million CpGs, which is four times the density of the 450k
array. The consensus of the results from the four diﬀerent
sets was taken, yielding genome-wide 𝛼 = 3.6 × 10−8. Inter-
estingly, this ﬁgure is close to that typically used for GWAS:
𝛼 = 5 × 10−8, although it is not clear why this would be the
case, considering these are distinct molecular measurements.
It is unlikely that this coincidence is due to pervasive eﬀects
of methylation quantitative trait loci, thus simply reﬂecting
LD, because similar results were seen in Caucasian and
Afr-Am-GTP populations. Further investigation is required
to determine whether there is some common mechanism at
play or that this is merely coincidence.
Comparing this with previous recommendations, we see
that the estimate for a genome-wide signiﬁcance for EWAS
obtained here is smaller than what has been suggested a lib-
eral threshold of 10−6, and would fall within the range con-
sidered stringent, 10−8 to 10−7 (Rakyan et al., 2011). This
threshold is however much less stringent than the genome-
wide Bonferroni level, which assuming there are 28 million
CpGs across the genome is 𝛼 = 1.79 × 10−9. Bonferroni cor-
rection would then indeed be overly conservative for methy-
lation data, but perhaps not to the extent previously sug-
gested. Applying these thresholds to previous power studies
for EWAS (Tsai & Bell, 2015), our results indicate that using
the 450k-speciﬁc 𝛼 = 2.4 × 10−7 would require sample sizes
∼10% larger than those previously estimated, and using the
genome-wide 𝛼 = 3.6 × 10−8 would require samples ∼20%
larger to obtain the same power.
As for the limitations of our method, permutation correc-
tion attempts to identify a limit for the number of independent
tests using a very small sample. The 450k oﬀers only ∼2%
coverage of the methylome, from which we have attempted to
extrapolate a more general relationship between the 5% point
of the minimum 𝑃 values and the density of coverage. That
our extrapolation reached a similar result for the four most
reliable datasets we studied suggests that consistent informa-
tion was present in the data. Although other models for extrap-
olation could be used, in GWAS data the Monod function
was found to give similar results to extrapolation from full
sequence data in limited regions (Pe'er, Yelensky, Altshuler,
& Daly, 2008) as well as to population genetics simulations
(Hoggart et al., 2008).
A related issue regarding extrapolation is whether the esti-
mated genome-wide threshold is more generally applicable in
EWAS, for DNA methylation measurements generated from
diﬀerent tissues or populations, studying diﬀerent diseases
or utilising alternative array platforms or even technologies
such as MeDIP-seq (methylated DNA immunoprecipitation
sequencing), WGBS (whole genome bisulphite-sequencing)
or RRBS (reduced representation bisulphite sequencing). In
terms of cross-tissue applicability, given the now wide-spread
availability of public 450k datasets, further work could be
done in comparing thresholds derived for diﬀerent tissues.
In a similar vein, we could also repeat the study for dif-
ferent populations, or perhaps even perform a huge meta-
analysis using all healthy controls from every available study
on GEO. Disease status is perhaps an important considera-
tion, as wide-scale disruption to the methylome such as that
often observed in cancer could potentially invalidate some of
the assumptions made, particularly regarding the level and
extent of co-methylation present, as the results we obtained
here for the CRC data indicate. As for cross-platform applica-
bility, this is perhaps less certain, as arrays such as the 450k
are designed to target genomic features such as promoter and
enhancer regions and CpG sites in higher density contexts
(Bibikova et al., 2009), resulting in relatively sparse and irreg-
ular genome-wide coverage (Ong & Holbrook, 2014). In con-
trast to GWAS, where the design of SNP arrays is instead
intended to maximise LD coverage across the genome, this
could then mean that the results of extrapolation for EWAS
are more reliant on the design parameters of the platform
used, in terms of distribution of probes and regions covered
(because co-methylation structure is likely to vary accord-
ing to genomic and functional context). The question of the
extent to which the results depend on array design could be
addressed in future studies using data from the latest platforms
such as the EPIC array and comparing the results to those pre-
sented here. Ideally, simulation extrapolation would use data
from a platform with even, un-biased coverage of all features,
which would increase conﬁdence in the derived genome-wide
threshold. Such a threshold might then even ﬁnd application
in whole-genome approaches such as WGBS, where although
complete coverage of themethylome can be achieved, because
permutation testing is computationally expensive, time con-
suming and study speciﬁc, an a priori estimate could still be
desirable.
As experience in GWAS has shown, the use of a standard
signiﬁcance threshold aids comparison and combination of
results across experiments, and enables power calculations to
inform the design of future experiments. The 𝛼 = 2.4 × 10−7
threshold for the 450k array that we have estimated here takes
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into account both dependency between tests due to patterns
of co-methylation, and the multiplicity of the set of CpGs
tested. As it is derived from results averaged over European,
African and American populations, it could therefore ﬁnd
general application for 450k array data, oﬀering an empir-
ically derived, more permissive alternative to Bonferroni
correction. One major limitation of this threshold is that it
does not take into account genome-wide multiplicity. The
non-random placement of probes and the current limited
coverage of the 450k makes extrapolation to saturated probe
coverage somewhat speculative, but we believe our estimated
genome-wide 𝛼 = 3.6 × 10−8 is a useful ﬁrst step towards
standardising levels of evidence in EWAS.
With the recent release of the EPIC array, the issue of sig-
niﬁcance in EWAS is as relevant as ever. Future work may
then seek to apply the methods described here to similarly
derive threshold estimates for the EPIC. In this regard, it
is interesting to note that estimates for GWAS signiﬁcance
thresholds were based on early generation genotyping arrays,
but remained unchallenged as denser arrays became available.
We expect that comparison of future estimates of EWAS sig-
niﬁcance to the present results may go some way to addressing
the question of whether it is possible to establish by extrapola-
tion a universal, platform-agnostic EWAS threshold for single
site-level diﬀerential methylation analysis.
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